FN2 Earnings Intelligence
Vertex Pharmaceuticals Incorporated income statement (quarterly)
Vertex Pharmaceuticals Incorporated (VRTX) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $4,674.7 | $4,972.2 | $4,939.6 | $5,492.9 | $6,143.5 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $2,770.2 | $2,964.7 | $3,076.4 | $2,986.9 | $3,333.9 | $3,409 | $3,508.2 |
| % Growth | - | - | - | - | - | 10.8% | - |
| Gross Profit | $2,407.2 | $2,557.2 | $2,661.6 | $2,594.1 | $2,844.7 | - | - |
| % Margin | 86.9% | 86.3% | 86.5% | 86.8% | 85.3% | - | - |
| EBITDA | $678.5 | $1,202.8 | $1,240.2 | $1,194 | $1,303.4 | - | - |
| % Margin | 24.5% | 40.6% | 40.3% | 40.0% | 39.1% | - | - |
| Net Income | $646.3 | $1,032.9 | $1,082.9 | $1,031.4 | $1,099.8 | - | - |
| % Margin | 23.3% | 34.8% | 35.2% | 34.5% | 33.0% | - | - |
| Diluted EPS | $2.49 | $3.99 | $4.20 | $4.02 | $4.31 | $4.80 | $4.82 |
| % Growth | - | - | - | - | - | 14.3% | - |
| Operating Cash Flow | $818.9 | - | - | $1,428.1 | - | - | - |
| CapEx | $40.7 | - | - | $133.4 | - | - | - |
| Free Cash Flow | $778.2 | - | - | $1,294.7 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $2,770.2 | $2,964.7 | $3,076.4 | $2,986.9 | $3,333.9 | $3,409 | $3,508.2 |
| Gross Profit | $2,407.2 | $2,557.2 | $2,661.6 | $2,594.1 | $2,844.7 | - | - |
| EBITDA | $678.5 | $1,202.8 | $1,240.2 | $1,194 | $1,303.4 | - | - |
| Net Income | $646.3 | $1,032.9 | $1,082.9 | $1,031.4 | $1,099.8 | - | - |
| Diluted EPS | $2.49 | $3.99 | $4.20 | $4.02 | $4.31 | $4.80 | $4.82 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4,674.7 | $4,972.2 | $4,939.6 | $5,492.9 | $6,143.5 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $818.9 | - | - | $1,428.1 | - |
| Capital Expenditure | $40.7 | - | - | $133.4 | - |
| Free Cash Flow | $778.2 | - | - | $1,294.7 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 86.9% | 86.3% | 86.5% | 86.8% | 85.3% |
| EBITDA Margin | 24.5% | 40.6% | 40.3% | 40.0% | 39.1% |
| Net Margin | 23.3% | 34.8% | 35.2% | 34.5% | 33.0% |
| FCF Margin | 28.1% | - | - | 43.3% | - |
| Diluted EPS Growth | - | - | - | - | - |